View More View Less
  • 1 Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Általános Orvostudományi Kar II. Belgyógyászati Klinika, Hematológiai Tanszék Debrecen Pf. 20 4012
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Az akut myeloid leukaemiával kapcsolatos ismeretek az utóbbi években a citogenetikának és molekuláris biológiának köszönhetően jelentősen bővültek. A betegség nemcsak morfológiailag és immunfenotípusát tekintve heterogén, hanem citogenetikai és molekuláris biológiai szempontból is. Prognózisa, különösen időskorban, ma is kedvezőtlen. A fiatalabb (50–60 év alatti) betegek túlélése az intenzív kemoterápia (nagy dózisú daunorubicin és cytarabin) következtében javult, de kedvezőtlen prognosztikai tényezők (a citogenetika mellett a molekuláris biológiai jellemzők szerepe is fontos) esetén csak az allogén transzplantáció lehet eredményes. A további fejlődés a betegség biológiájának jobb megismerésétől és az ezen alapuló célzott („targeted”) terápiától várható. Orv.Hetil., 2012, 153, 243–249.

  • Bennett, J. M., Catovsky, D., Daniel, M. T., et al.: Proposals for the classification of the acute leukaemias. Br. J. Haematol., 1976, 33, 451–458.

    Daniel M. T. , 'Proposals for the classification of the acute leukaemias ' (1976 ) 33 Br. J. Haematol. : 451 -458.

    • Search Google Scholar
  • Bennett, J. M., Catovsky, D., Daniel, M. T., et al.: Proposed revised criteria for the classification af acute myeloid leukaemia. Ann. Intern. Med., 1985, 103, 636–639.

    Daniel M. T. , 'Proposed revised criteria for the classification af acute myeloid leukaemia ' (1985 ) 103 Ann. Intern. Med. : 636 -639.

    • Search Google Scholar
  • Bennett, J. M., Catovsky, D., Daniel, M. T., et al.: Criteria for the diagnosis of acute leukaemia of megakaryocytic lineage (M7). A report of the French-American-British Cooperative Group. Ann. Intern. Med., 1985, 103, 460–462.

    Daniel M. T. , 'Criteria for the diagnosis of acute leukaemia of megakaryocytic lineage (M7). A report of the French-American-British Cooperative Group ' (1985 ) 103 Ann. Intern. Med. : 460 -462.

    • Search Google Scholar
  • Bennett, J. M., Catovsky, D., Daniel, M. T., et al.: Proposals for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Brit. J. Haemat., 1991, 78, 325–329.

    Daniel M. T. , 'Proposals for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0) ' (1991 ) 78 Brit. J. Haemat. : 325 -329.

    • Search Google Scholar
  • Jaffe, E. S., Harris, N. L.: Tumours of haematopoietic and lymphoid tissues. World Health Organisation classificaion of tumours. JARC Press, Lyon, 2001.

    Harris N. L. , '', in Tumours of haematopoietic and lymphoid tissues. World Health Organisation classificaion of tumours , (2001 ) -.

  • Grimwade, D., Hills, R. K.: Independent prognostic factors for AML outcome. Hematology Am. Soc. Hematol. Educ. Program Book, New Orleans, 2009, 385–395.

    Hills R. K. , '', in Independent prognostic factors for AML outcome. Hematology Am. Soc. Hematol. Educ. Program Book , (2009 ) -.

  • Döhner, H., Estey, E. H., Amadori, S., et al.: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European Leukemia-Net. Blood, 2010, 115, 453–474.

    Amadori S. , 'Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European Leukemia-Net ' (2010 ) 115 Blood : 453 -474.

    • Search Google Scholar
  • Kottaridis, P. D., Gale, R. E., Frew, M. E., et al.: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 2001, 98, 1752–1759.

    Frew M. E. , 'The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials ' (2001 ) 98 Blood : 1752 -1759.

    • Search Google Scholar
  • Dohner, K., Schlenk, R. F., Habdank, M., et al.: Mutant nucleophsomin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood, 2005, 106, 3740–3746.

    Habdank M. , 'Mutant nucleophsomin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations ' (2005 ) 106 Blood : 3740 -3746.

    • Search Google Scholar
  • Green, C. L., Koo, K. K., Hills, R. K., et al.: Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interactions with FLT3 and NPM1 mutations. J. Clin. Oncol., 2010, 28, 2739–2747.

    Hills R. K. , 'Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interactions with FLT3 and NPM1 mutations ' (2010 ) 28 J. Clin. Oncol. : 2739 -2747.

    • Search Google Scholar
  • Ward, P. S., Patel, J., Wise, D. R., et al.: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell, 2010, 17, 225–234.

    Wise D. R. , 'The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate ' (2010 ) 17 Cancer Cell : 225 -234.

    • Search Google Scholar
  • Figueroa, M. E., Abdel-Wahab, O., Lu, C., et al.: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell, 2010, 18, 553–567.

    Lu C. , 'Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation ' (2010 ) 18 Cancer Cell : 553 -567.

    • Search Google Scholar
  • Ley, T. J., Ding, L., Walter, M. J., et al.: DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med., 2010, 363, 2424–2433.

    Walter M. J. , 'DNMT3A mutations in acute myeloid leukemia ' (2010 ) 363 N. Engl. J. Med. : 2424 -2433.

    • Search Google Scholar
  • Löwenberg, B.: Genetic markers in relations to the therapeutic management of acute myeloid leukemia. Hematology education: the education program for the annual congress of the European Hematology Association. London, 2011, 5, 36–41.

  • Rocquain, J., Carbuccia, N., Trouplin, V., et al.: Combined mutations of ASXL1, CBL, FLT3, LDH1, LDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer, 2010, 10, 401.

    Trouplin V. , 'Combined mutations of ASXL1, CBL, FLT3, LDH1, LDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias ' (2010 ) 10 BMC Cancer : 401 -.

    • Search Google Scholar
  • Chou, W. C., Huang, H. H., Hou, H. A., et al.: Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood, 2010, 116, 4086–4094.

    Hou H. A. , 'Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations ' (2010 ) 116 Blood : 4086 -4094.

    • Search Google Scholar
  • Schlenk, R. F., Dohner, K., Krauter, J.: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med., 2008, 358, 1909–1918.

    Krauter J. , 'Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia ' (2008 ) 358 N. Engl. J. Med. : 1909 -1918.

    • Search Google Scholar
  • Nahajevszky, S., Andrikovics, H., Batai, A., et al.: The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia. Hematologica, 2011, 96, 1613–1618.

    Batai A. , 'The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia ' (2011 ) 96 Hematologica : 1613 -1618.

    • Search Google Scholar
  • Russel, N.: Transplantation for acute myeloid leukemia. Hematology education: the education program for the annual congress of the European Hematology Association. London, 2011, 5, 42–50.

  • Rowe, J. M.: Optimal induction and post-remission therapy for AML in first remission. Hematology Am. Soc. Hematol. Educ. Program Book, New Orleans, 2009, 396–405.

    Rowe J. M. , '', in Optimal induction and post-remission therapy for AML in first remission. Hematology Am. Soc. Hematol. Educ. Program Book , (2009 ) -.

  • Foran, J. M.: New prognostic markers in acute myeloid leukemia. Perspective from the clinic. Hematology Am. Soc. Hematol. Educ. Program Book, Orlando, 2010, 47–55.

    Foran J. M. , '', in New prognostic markers in acute myeloid leukemia. Perspective from the clinic. Hematology Am. Soc. Hematol. Educ. Program Book , (2010 ) -.

  • Krauter, J., Heitel, G., Hoelzer, D., et al.: The role of consolidation therapy in the treatment of patients up to 60 years with high risk AML. Blood, 2005, 106, Abstract, 172.

    Hoelzer D. , 'The role of consolidation therapy in the treatment of patients up to 60 years with high risk AML ' (2005 ) 106 Blood : 172 -.

    • Search Google Scholar
  • Mandelli, F., Vignetti, M., Suciu, S., et al.: Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J. Clin. Oncol., 2009, 27, 5397–5403.

    Suciu S. , 'Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10 ' (2009 ) 27 J. Clin. Oncol. : 5397 -5403.

    • Search Google Scholar
  • Pautas, C., Merabet, F., Thomas, X., et al.: Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J. Clin. Oncol., 2010, 28, 808–814.

    Thomas X. , 'Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study ' (2010 ) 28 J. Clin. Oncol. : 808 -814.

    • Search Google Scholar
  • Fernandez, H. F.: New trends in the standard of care for initial therapy of acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program Book, Orlando, 2010, 56–61.

    Fernandez H. F. , '', in New trends in the standard of care for initial therapy of acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program Book , (2010 ) -.

  • Fernandez, H. F., Sun, Z., Yao, X., et al.: Anthracycline dose intensification in acute myeloid leukemia. N. Eng. J. Med., 2009, 361, 1249–1259.

    Yao X. , 'Anthracycline dose intensification in acute myeloid leukemia ' (2009 ) 361 N. Eng. J. Med. : 1249 -1259.

    • Search Google Scholar
  • Weick, J. K., Kopecky, K. J., Appelbaum, F. R., et al.: A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study. Blood, 1996, 88, 2841–2851.

    Appelbaum F. R. , 'A randomized investigation of high-dose versus standard dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study ' (1996 ) 88 Blood : 2841 -2851.

    • Search Google Scholar
  • Kern, W., Estey, E. H.: High-dose cytosine arabinoside in the treatment of acute myeloid leukemia. review of three randomized trials. Cancer, 2006, 107, 116–124.

    Estey E. H. , 'High-dose cytosine arabinoside in the treatment of acute myeloid leukemia. review of three randomized trials ' (2006 ) 107 Cancer : 116 -124.

    • Search Google Scholar
  • Paschka, P., Marcucci, G., Ruppert, A. S., et al.: Wilms, tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia. A Cancer and Leukemia Group B Study. J. Clin. Oncol., 2008, 26, 4595–4602.

    Ruppert A. S. , 'Wilms, tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia. A Cancer and Leukemia Group B Study ' (2008 ) 26 J. Clin. Oncol. : 4595 -4602.

    • Search Google Scholar
  • Becker, H., Marcucci, G., Maharry, K., et al.: Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood, 2010, 116, 788–792.

    Maharry K. , 'Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study ' (2010 ) 116 Blood : 788 -792.

    • Search Google Scholar
  • Damm, F., Heuser, M., Morgan, M., et al.: Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J. Clin. Oncol., 2010, 28, 578–585.

    Morgan M. , 'Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia ' (2010 ) 28 J. Clin. Oncol. : 578 -585.

    • Search Google Scholar
  • Buccisano, F., Maurillo, L., Spagnoli, A., et al.: Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood, 2010, 116, 2295–2303.

    Spagnoli A. , 'Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia ' (2010 ) 116 Blood : 2295 -2303.

    • Search Google Scholar
  • Estey, E. H., Garcia-Manero, G., Ferrajoli, A., et al.: Use of all-transretinoic acid (ATRA) + arsenic trioxide (ATO) to eliminate or minimize use of chemotherapy (CT) in untreated acute promyelocytic leukemia (APL). Blood, 2004, 104, 115a.

    Ferrajoli A. , 'Use of all-transretinoic acid (ATRA) + arsenic trioxide (ATO) to eliminate or minimize use of chemotherapy (CT) in untreated acute promyelocytic leukemia (APL) ' (2004 ) 104 Blood : 115a -.

    • Search Google Scholar
  • Luger, S. M.: Treating the elderly patient with acute myelogenous leukemia. Hematology Am. Soc. Hematol. Educ. Program Book, Orlando, 2010, 62–69.

    Luger S. M. , '', in Treating the elderly patient with acute myelogenous leukemia. Hematology Am. Soc. Hematol. Educ. Program Book , (2010 ) -.

  • Burnett, A. K., Kell, W. J., Goldstone, A. H., et al.: The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial. Blood, 2006, 108, Abstract, 13.

    Goldstone A. H. , 'The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial ' (2006 ) 108 Blood : 13 -.

    • Search Google Scholar
  • Borthakur, G., Jabbour, E., Wang, X., et al.: Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML). J. Clin. Oncol., 2010, 28, Abstract, 6552.

    Wang X. , 'Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML) ' (2010 ) 28 J. Clin. Oncol. : 6552 -.

    • Search Google Scholar
  • Issa, J. P., Garcia-Manero, G., Giles, F. J., et al.: Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in hematopoietic malignancies. Blood, 2004, 103, 1635–1640.

    Giles F. J. , 'Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in hematopoietic malignancies ' (2004 ) 103 Blood : 1635 -1640.

    • Search Google Scholar
  • Garcia-Mancro, G., Kantarjian, H., Sanchez-Gonzalez, B., et al.: Results of phase I/II study of the combination of 5-aza-2’-deoxycytidine (DAC) and valporic acid (VA) in patients with leukemia. Blood, 2004, 104, 78a.

    Sanchez-Gonzalez B. , 'Results of phase I/II study of the combination of 5-aza-2’-deoxycytidine (DAC) and valporic acid (VA) in patients with leukemia ' (2004 ) 104 Blood : 78a -.

    • Search Google Scholar
  • Kirschbaum, M., Gojo, I., Goldberg, S., et al.: Phase I study of vorinostat in combination with decitabine in patients with relapsed or newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. Blood, 2008, 112, Abstract, 3651.

    Goldberg S. , 'Phase I study of vorinostat in combination with decitabine in patients with relapsed or newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome ' (2008 ) 112 Blood : 3651 -.

    • Search Google Scholar
  • Thepot, S., Itzykson, R., Seegers, V., et al.: Azacytidine (AZ) as first line therapy in AML: results of the French ATU program. Blood, 2009, 114, Abstract, 843.

    Seegers V. , 'Azacytidine (AZ) as first line therapy in AML: results of the French ATU program ' (2009 ) 114 Blood : 843 -.

    • Search Google Scholar